{"id":"comparator-influenza-vaccine","safety":{"commonSideEffects":[{"rate":"10-30","effect":"Injection site soreness or erythema"},{"rate":"5-15","effect":"Myalgia"},{"rate":"5-10","effect":"Headache"},{"rate":"1-5","effect":"Fever"},{"rate":"5-10","effect":"Fatigue"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"The vaccine contains inactivated or attenuated influenza virus antigens that trigger both humoral (antibody-mediated) and cellular immune responses. This primes the immune system to recognize and rapidly respond to natural influenza infection, reducing disease severity and transmission risk. Annual reformulation targets circulating seasonal strains.","oneSentence":"Influenza vaccine stimulates the immune system to produce antibodies and cellular immunity against influenza virus strains, providing protection against infection.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:07:02.101Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Seasonal influenza prevention in adults and children"}]},"trialDetails":[{"nctId":"NCT07371650","phase":"PHASE2","title":"This is an Early-stage Clinical Trial to Determine a Safe and Effective Dose for Tivoxavir Marboxil in Patients With Mild to Moderate Influenza","status":"ACTIVE_NOT_RECRUITING","sponsor":"Traws Pharma, Inc.","startDate":"2025-12-15","conditions":"Influenza","enrollment":105},{"nctId":"NCT07204964","phase":"PHASE2","title":"A Study to Evaluate the Immune Response and Safety of an Influenza Vaccine in Adults 18 Years of Age and Above","status":"ACTIVE_NOT_RECRUITING","sponsor":"GlaxoSmithKline","startDate":"2025-10-07","conditions":"Influenza, Human","enrollment":971},{"nctId":"NCT07485855","phase":"PHASE3","title":"Influenza Vaccination Strategy for Patients With Hematologic Malignancy","status":"RECRUITING","sponsor":"Asan Medical Center","startDate":"2025-12-04","conditions":"Hematologic Neoplasms, Influenza, Immunogenicity","enrollment":60},{"nctId":"NCT05945485","phase":"PHASE1","title":"A Study to Evaluate the Safety and Immunogenicity of Two Doses of DCVC H1 HA mRNA-LNP in Healthy Adults","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2023-10-16","conditions":"Influenza","enrollment":50},{"nctId":"NCT07110532","phase":"PHASE1","title":"pH1N1 Blinded Challenge Study","status":"RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2025-09-10","conditions":"Influenza","enrollment":180},{"nctId":"NCT07291635","phase":"PHASE1, PHASE2","title":"Phase 1/2 Study of a Plant-Based Seasonal Recombinant Trivalent VLP Influenza Vaccine","status":"RECRUITING","sponsor":"Aramis Biotechnologies Inc.","startDate":"2026-02-25","conditions":"Influenza","enrollment":728},{"nctId":"NCT06431607","phase":"PHASE2","title":"A Study to Find the Dose and Assess the Immune Response and Safety of a Vaccine Against Influenza in Healthy Younger and Older Adults","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2024-05-23","conditions":"Influenza, Human","enrollment":845},{"nctId":"NCT07430410","phase":"NA","title":"Clinical Validation of an At-Home Flu A/B and COVID-19 Rapid Test","status":"NOT_YET_RECRUITING","sponsor":"CorDx, Inc.","startDate":"2026-02-12","conditions":"SARS-CoV-2 Infection, Influenza A, Influenza B","enrollment":200},{"nctId":"NCT06602531","phase":"PHASE1","title":"Safety and Immunogenicity Study of Self-Amplifying RNA Pandemic Influenza Vaccine in Adults","status":"COMPLETED","sponsor":"Arcturus Therapeutics, Inc.","startDate":"2024-12-10","conditions":"Influenza, Human","enrollment":212},{"nctId":"NCT05606965","phase":"PHASE2","title":"A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1010 in Healthy Adults","status":"COMPLETED","sponsor":"ModernaTX, Inc.","startDate":"2022-11-02","conditions":"Influenza","enrollment":172},{"nctId":"NCT07121192","phase":"PHASE2","title":"A Study to Assess the Immune Response and Safety of a Vaccine Against Influenza in Adults 18 Years of Age and Older","status":"ACTIVE_NOT_RECRUITING","sponsor":"GlaxoSmithKline","startDate":"2025-08-25","conditions":"Influenza, Human","enrollment":776},{"nctId":"NCT05755620","phase":"PHASE1","title":"A Study to Evaluate the Safety and Immunogenicity of a Single Dose of H1ssF-3928 mRNA-LNP in Healthy Adults","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2023-04-05","conditions":"Influenza","enrollment":50},{"nctId":"NCT07217639","phase":"NA","title":"Clinical Validation of the Aptitude Medical Systems Metrix Respiratory Panel Test in At-Home/Non-Laboratory Settings","status":"NOT_YET_RECRUITING","sponsor":"Aptitude Medical Systems","startDate":"2025-11-01","conditions":"COVID -19, Influenza A, Influenza B","enrollment":2000},{"nctId":"NCT05608005","phase":"PHASE1, PHASE2","title":"Study on Two Adjuvanted Dose Levels of Panblok H7+MF59 Compared for Immunogenicity and Safety With an Unadjuvanted Dose of Panblok H7 in Participants 18 Years of Age and Older","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2022-11-03","conditions":"Influenza, Healthy Volunteers","enrollment":581},{"nctId":"NCT06602024","phase":"PHASE3","title":"A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ≥50 Years of Age","status":"COMPLETED","sponsor":"ModernaTX, Inc.","startDate":"2024-09-16","conditions":"Seasonal Influenza","enrollment":40817},{"nctId":"NCT06684379","phase":"PHASE1, PHASE2","title":"Study on Safety and Efficacy of Two Doses of PRS CK STORM in the Modulation of the Cytokine Storm for the Treatment of Acute Respiratory Distress Syndrome (ARDS) Caused by SARS-Cov-2, Influenza A, Influenza B and Respiratory Syncytial Virus (RSV)","status":"RECRUITING","sponsor":"PEACHES BIOTECH","startDate":"2024-10-02","conditions":"SARS-CoV-2, Influenza, Human, Respiratory Syncytial Virus Infections","enrollment":50},{"nctId":"NCT06191393","phase":"NA","title":"SARS-CoV-2 and Influenza A/B in Point-of-Care and Non-Laboratory Settings","status":"COMPLETED","sponsor":"Aptitude Medical Systems","startDate":"2023-11-20","conditions":"SARS-CoV-2 Infection, Influenza A, Influenza B","enrollment":614},{"nctId":"NCT03932682","phase":"PHASE3","title":"Efficacy Study With QIVc in Pediatric Subjects","status":"COMPLETED","sponsor":"Seqirus","startDate":"2019-05-13","conditions":"Influenza, Human","enrollment":5723},{"nctId":"NCT06827873","phase":"NA","title":"Effect of Oral Supplements for Influenza Vaccine Response","status":"NOT_YET_RECRUITING","sponsor":"Tsinghua University","startDate":"2025-02","conditions":"Influenza Vaccine Response","enrollment":45},{"nctId":"NCT06130345","phase":"","title":"Post-marketing Safety of Elasomeran/Davesomeran and Andusomeran","status":"COMPLETED","sponsor":"ModernaTX, Inc.","startDate":"2023-04-14","conditions":"SARS-CoV-2","enrollment":15196685},{"nctId":"NCT05284799","phase":"PHASE2","title":"Immunogenicity and Safety of the Concomitant Administration of OVX836 and Quadrivalent Influenza Vaccine in Healthy Volunteers.","status":"COMPLETED","sponsor":"Osivax","startDate":"2022-05-09","conditions":"Influenza","enrollment":180},{"nctId":"NCT04782323","phase":"PHASE2","title":"Safety and Immunogenicity of Different Formulations of an MF59-Adjuvanted Influenza Vaccine in Older Adults","status":"COMPLETED","sponsor":"Seqirus","startDate":"2021-04-13","conditions":"Influenza","enrollment":839},{"nctId":"NCT01538940","phase":"PHASE4","title":"Immunogenicity of Influenza Vaccines in HIV-infected Persons in Thailand","status":"COMPLETED","sponsor":"Centers for Disease Control and Prevention","startDate":"2011-11-01","conditions":"Influenza","enrollment":415},{"nctId":"NCT04787913","phase":"NA","title":"An Evaluation of a Dynamic Web-Based Visualization of Community Immunity","status":"COMPLETED","sponsor":"Laval University","startDate":"2021-03-01","conditions":"Vaccine-Preventable Diseases","enrollment":5516},{"nctId":"NCT05519839","phase":"PHASE2","title":"A Study to Evaluate the Safety and Immunogenicity of COVID-19 and Influenza Combination Vaccine","status":"COMPLETED","sponsor":"Novavax","startDate":"2022-12-30","conditions":"COVID-19, Influenza","enrollment":1579},{"nctId":"NCT06392451","phase":"NA","title":"LIAISON NES Influenza (FLU) A/B, Respiratory Syncytial Virus (RSV), & Coronavirus Disease 2019 (COVID-19) in Symptomatic Patients in Australia","status":"NOT_YET_RECRUITING","sponsor":"DiaSorin Molecular LLC","startDate":"2024-05-06","conditions":"Influenza A, Influenza Type B, Coronavirus Disease 2019","enrollment":1000},{"nctId":"NCT05897515","phase":"NA","title":"LIAISON NES Influenza (FLU) A/B & Coronavirus Disease 2019 (COVID-19) Clinical Agreement in Australia","status":"COMPLETED","sponsor":"DiaSorin Molecular LLC","startDate":"2023-06-19","conditions":"Influenza A, Influenza Type B, Coronavirus Disease 2019","enrollment":233},{"nctId":"NCT05501561","phase":"PHASE2","title":"Safety and Immunogenicity of Different Formulations of an MF59-Adjuvanted Influenza Vaccine in Older Adults ≥50 Years of Age","status":"COMPLETED","sponsor":"Seqirus","startDate":"2022-08-25","conditions":"Influenza, Human","enrollment":1056},{"nctId":"NCT05333289","phase":"PHASE1, PHASE2","title":"A Study of mRNA-1020 and mRNA-1030 Seasonal Influenza Vaccines in Healthy Adults","status":"COMPLETED","sponsor":"ModernaTX, Inc.","startDate":"2022-04-06","conditions":"Seasonal Influenza","enrollment":572},{"nctId":"NCT05734040","phase":"PHASE2","title":"Immunogenicity and Safety of the Concomitant Administration of OVX836 Influenza Vaccine, Quadrivalent Inactivated Influenza Vaccines and Placebo in Healthy Subjects.","status":"COMPLETED","sponsor":"Osivax","startDate":"2023-05-10","conditions":"Influenza","enrollment":478},{"nctId":"NCT04956575","phase":"PHASE1, PHASE2","title":"A Study of mRNA-1010 Seasonal Influenza Vaccine in Healthy Adults","status":"COMPLETED","sponsor":"ModernaTX, Inc.","startDate":"2021-07-06","conditions":"Seasonal Influenza","enrollment":885},{"nctId":"NCT05045144","phase":"PHASE3","title":"A Phase III Study to Assess the Lot-to-lot Consistency of GSK's Investigational RSV Maternal Vaccine and the Immune Response and Safety of RSV Maternal Vaccine When Given Alone or Co-administered With GSK's Influenza D-QIV Vaccine in Healthy Non-pregnant Women.","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2021-10-26","conditions":"Respiratory Syncytial Virus Infections","enrollment":1586},{"nctId":"NCT05044195","phase":"PHASE3","title":"A Clinical Study to Evaluate the Immunogenicity and Safety of an Adjuvanted Quadrivalent Influenza Vaccine Compared With a Licensed Quadrivalent Vaccine in Adults 50 to 64 Years of Age","status":"COMPLETED","sponsor":"Seqirus","startDate":"2021-09-30","conditions":"Influenza, Human","enrollment":2044},{"nctId":"NCT04622592","phase":"PHASE1, PHASE2","title":"Adjuvanted Seasonal Recombinant Quadrivalent Virus-Like Particles (QVLP) Influenza Vaccine in Adults 65 Years of Age and Older","status":"COMPLETED","sponsor":"Medicago","startDate":"2020-11-02","conditions":"Influenza","enrollment":209},{"nctId":"NCT05946538","phase":"NA","title":"Clinical Evaluation of SARS-COV-2 (COVID-19), Influenza and RSV 8-Well MT-PCR Panel for In Vitro Diagnostics","status":"UNKNOWN","sponsor":"AusDiagnostics Pty Ltd.","startDate":"2023-07","conditions":"Respiratory Viral Infection","enrollment":1000},{"nctId":"NCT04683406","phase":"PHASE3","title":"A Study of ZSP1273 Tablets in Patients With Acute Uncomplicated Influenza A","status":"COMPLETED","sponsor":"Guangdong Raynovent Biotech Co., Ltd","startDate":"2020-12-28","conditions":"Influenza A","enrollment":750},{"nctId":"NCT03739112","phase":"PHASE3","title":"Efficacy of a Plant-derived Quadrivalent Virus-like Particle (VLP) Vaccine in the Elderly","status":"COMPLETED","sponsor":"Medicago","startDate":"2018-09-18","conditions":"Virus Diseases, RNA Virus Infections, Respiratory Tract Diseases","enrollment":12794},{"nctId":"NCT01344057","phase":"PHASE2","title":"Study to Evaluate Safety and Immunogenicity of Sub-unit Adjuvanted Influenza Vaccine Administered to Elderly Subjects, Formulation 2011-2012","status":"COMPLETED","sponsor":"Novartis Vaccines","startDate":"2011-05","conditions":"Seasonal Influenza","enrollment":63},{"nctId":"NCT01964989","phase":"PHASE3","title":"Clinical Study to Evaluate the Safety, Immunogenicity and Efficacy of Investigational Flu Vaccine Compared to Approved Flu Vaccine in Children.","status":"COMPLETED","sponsor":"Seqirus","startDate":"2013-11","conditions":"Influenza Virus","enrollment":10644},{"nctId":"NCT02918006","phase":"PHASE2","title":"A Phase 2 Influenza A Challenge Study Following Oral Administration of an H1N1 HA Ad-Vector Seasonal Flu Vaccine","status":"COMPLETED","sponsor":"Vaxart","startDate":"2016-08-31","conditions":"Influenza","enrollment":179},{"nctId":"NCT04548518","phase":"PHASE3","title":"Immunogenicity and Safety of Tri Fluvac, a Seasonal Trivalent Inactivated Split Virion Influenza Vaccine, in Healthy Thai Elderly","status":"UNKNOWN","sponsor":"Mahidol University","startDate":"2020-08-03","conditions":"Influenza","enrollment":816},{"nctId":"NCT05154383","phase":"PHASE4","title":"Effect of High-Dose Quadrivalent Influenza Vaccine (Efluelda®) Versus Standard-Dose (QIV-SD), in Subjects 65 Years of Age and Older on Innate Immunity, Including Gene Expression","status":"COMPLETED","sponsor":"Centre Hospitalier Annecy Genevois","startDate":"2021-11-15","conditions":"Vaccine Reaction","enrollment":60},{"nctId":"NCT03344029","phase":"PHASE4","title":"Immunogenicity and Safety of the Shenzhen Trivalent Inactivated Influenza Vaccine Versus a Trivalent Influenza Vaccine Comparator in Chinese Subjects 18 to 59 Years","status":"COMPLETED","sponsor":"Sanofi","startDate":"2017-11-03","conditions":"Influenza, Flu","enrollment":1600},{"nctId":"NCT04074928","phase":"PHASE3","title":"Safety and Immunogenicity Study of QIVc in Healthy Pediatric Subjects","status":"COMPLETED","sponsor":"Seqirus","startDate":"2019-09-06","conditions":"Influenza, Human, Virus Diseases","enrollment":2414},{"nctId":"NCT04387760","phase":"PHASE2","title":"Favipiravir vs Hydroxychloroquine vs Control in COVID -19","status":"COMPLETED","sponsor":"Royal College of Surgeons in Ireland - Medical University of Bahrain","startDate":"2020-08-11","conditions":"SARS-CoV 2, COVID-19","enrollment":150},{"nctId":"NCT03527355","phase":"PHASE2","title":"Safety, Reactogenicity and Immunogenicity of Vi-DT;Typhoid Conjugate Vaccine","status":"COMPLETED","sponsor":"International Vaccine Institute","startDate":"2018-04-18","conditions":"Typhoid","enrollment":285},{"nctId":"NCT04806529","phase":"PHASE2, PHASE3","title":"An Efficacy, Immunogenicity and Safety Study Investigating an Adjuvanted SARS-CoV-2 Influenza Vaccine to Protect Against COVID-19 in Adults Over Aged 18 Years-old and Older","status":"WITHDRAWN","sponsor":"Seqirus","startDate":"2020-12-15","conditions":"Influenza","enrollment":""},{"nctId":"NCT03448705","phase":"PHASE1","title":"Safety of 4Fluart ID Suspension for Injection in Adult Subjects","status":"COMPLETED","sponsor":"Fluart Innovative Vaccine Ltd, Hungary","startDate":"2018-01-31","conditions":"Human Influenza","enrollment":36},{"nctId":"NCT04650971","phase":"PHASE1","title":"Study to Assess Safety, Tolerability and Reactogenicity of Vaccine \"UniFluVec\" After Two Intranasal Administrations in Healthy Volunteers","status":"COMPLETED","sponsor":"Pharmenterprises Biotech LLC","startDate":"2019-08-29","conditions":"Influenza A","enrollment":60},{"nctId":"NCT03165617","phase":"PHASE3","title":"Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of QIVc in Subjects ≥2 to <18 Years of Age","status":"COMPLETED","sponsor":"Seqirus","startDate":"2017-05-25","conditions":"Influenza, Human","enrollment":4514},{"nctId":"NCT04551248","phase":"","title":"Post-marketing Safety Evaluation of Pneumococcal Vaccines Among Children and Elderly Adults.","status":"UNKNOWN","sponsor":"Sungkyunkwan University","startDate":"2021-08-01","conditions":"Pneumococcal Vaccine Adverse Reaction","enrollment":1000000},{"nctId":"NCT04297462","phase":"NA","title":"Different Regimens in Influenza Postexposure Chemoprophylaxis in Children","status":"UNKNOWN","sponsor":"Centre of Postgraduate Medical Education","startDate":"2016-11-17","conditions":"Influenza, Exposure, Prevention","enrollment":50},{"nctId":"NCT02480998","phase":"PHASE1, PHASE2","title":"Study to Evaluate the Safety and Immunogenicity of 'IL-YANG Flu Vaccine Quadrivalent Inj' in Healthy Korean Adults","status":"COMPLETED","sponsor":"Il-Yang Pharm. Co., Ltd.","startDate":"2015-02","conditions":"Influenza, Human","enrollment":84},{"nctId":"NCT02587221","phase":"PHASE3","title":"Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Influenza Vaccine Compared to Non-influenza Vaccine Comparator in Adults ≥ 65 Years of Age","status":"COMPLETED","sponsor":"Seqirus","startDate":"2016-09-30","conditions":"Influenza","enrollment":6790},{"nctId":"NCT01991561","phase":"PHASE2","title":"Immunogenicity, Safety, Tolerability of a Plant-made H5 Virus-like-particle (VLP) Influenza Vaccine.","status":"COMPLETED","sponsor":"Medicago","startDate":"2013-06","conditions":"Virus Diseases, RNA Virus Infections, Respiratory Tract Diseases","enrollment":390},{"nctId":"NCT02645032","phase":"PHASE1","title":"Safety and Immunogenicity of a Vi-DT Typhoid Conjugate Vaccine","status":"COMPLETED","sponsor":"International Vaccine Institute","startDate":"2016-05-19","conditions":"Typhoid","enrollment":144},{"nctId":"NCT03390166","phase":"PHASE2, PHASE3","title":"Immunogenicity and Safety of Tri Fluvac, a Seasonal Trivalent Inactivated Influenza Vaccine in Healthy Thai Adults","status":"COMPLETED","sponsor":"Mahidol University","startDate":"2017-07-24","conditions":"Influenza","enrollment":945},{"nctId":"NCT00821626","phase":"NA","title":"Rapid Flu Tests in Travelers With Fever","status":"COMPLETED","sponsor":"University of Lausanne Hospitals","startDate":"2009-01","conditions":"Influenza","enrollment":93},{"nctId":"NCT03220048","phase":"PHASE2","title":"Study Examining PrEP-001 in Healthy Subjects","status":"COMPLETED","sponsor":"Hvivo","startDate":"2015-09-16","conditions":"Influenza A H3N2","enrollment":66},{"nctId":"NCT02500680","phase":"PHASE1","title":"The Safety, Tolerance, and Immunogenicity of MAS-1-Adjuvanted Seasonal Inactivated Influenza Vaccine (MER4101)","status":"UNKNOWN","sponsor":"Nova Immunotherapeutics Limited","startDate":"2015-07","conditions":"Influenza, Human","enrollment":102},{"nctId":"NCT01480258","phase":"PHASE3","title":"Safety, Tolerability, and Immunogenicity of V419 in Healthy Infants When Given at 2, 4, and 11 to 12 Months (V419-008)","status":"COMPLETED","sponsor":"MCM Vaccines B.V.","startDate":"2011-11-23","conditions":"Bacterial Infections, Virus Diseases","enrollment":1315},{"nctId":"NCT02171819","phase":"PHASE1","title":"Influenza A/H5N1 Vaccine Clinical Trial (IVACFLU-A/H5N1) - Phase 1","status":"COMPLETED","sponsor":"Institute of Vaccines and Medical Biologicals, Vietnam","startDate":"2014-06","conditions":"Influenza A Subtype H5N1 Infection","enrollment":75},{"nctId":"NCT02998996","phase":"PHASE1, PHASE2","title":"Study to Assess the Safety, Tolerability and Immune Response Following Vaccination With Immunose™ FLU","status":"COMPLETED","sponsor":"Eurocine Vaccines AB","startDate":"2016-09","conditions":"Influenza, Human","enrollment":162},{"nctId":"NCT02598089","phase":"PHASE1","title":"Seasonal Trivalent Inactivated Split Virion Influenza Vaccine Clinical Trial (IVACFLU-S)","status":"COMPLETED","sponsor":"Institute of Vaccines and Medical Biologicals, Vietnam","startDate":"2015-11","conditions":"Influenza, Human","enrollment":60},{"nctId":"NCT02914275","phase":"PHASE3","title":"A Study to Evaluate the Immunogenicity and Safety of Seqirus Quadrivalent Influenza Vaccine (QIV) in a Pediatric Population 6 Months Through 59 Months of Age.","status":"COMPLETED","sponsor":"Seqirus","startDate":"2016-09-27","conditions":"Influenza, Human","enrollment":2250},{"nctId":"NCT03657719","phase":"PHASE2","title":"A Study to Evaluate the Safety and Efficacy(Immunogenicity) of GC3114 in Elderly Healthy Subjects","status":"COMPLETED","sponsor":"Green Cross Corporation","startDate":"2018-10-01","conditions":"Influenza, Human","enrollment":105},{"nctId":"NCT03437304","phase":"PHASE1, PHASE2","title":"Study to Assess the Safety, Tolerability and Immune Response Following Vaccination With Immunose™ FLU in Older Adults","status":"COMPLETED","sponsor":"Eurocine Vaccines AB","startDate":"2018-02-09","conditions":"Influenza","enrollment":298},{"nctId":"NCT03357263","phase":"PHASE1","title":"A Study to Evaluate the Safety and Efficacy(Immunogenicity) of GC3114 in Healthy Adults","status":"COMPLETED","sponsor":"Green Cross Corporation","startDate":"2017-11-20","conditions":"Influenza, Human","enrollment":40},{"nctId":"NCT01337167","phase":"PHASE3","title":"Safety, Tolerability, and Immunogenicity of V419 Given Concomitantly With Prevnar 13™ and RotaTeq™ (V419-005)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2011-04-19","conditions":"Bacterial Infections, Virus Diseases","enrollment":1473},{"nctId":"NCT01720329","phase":"NA","title":"Use of Probiotics to Prevent Influenza","status":"COMPLETED","sponsor":"McMaster University","startDate":"2013-07","conditions":"Influenza","enrollment":1440},{"nctId":"NCT00980005","phase":"PHASE3","title":"Study to Assess the Immunogenicity and Safety of an Investigational Influenza Vaccine in Children","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2009-10-13","conditions":"Influenza","enrollment":2116},{"nctId":"NCT02242643","phase":"PHASE3","title":"Study to Evaluate the Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Quadrivalent Influenza Vaccine (GSK2282512A) Compared to Fluzone® Quadrivalent in Children 6 to 35 Months of Age","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2014-10-01","conditions":"Influenza","enrollment":2432},{"nctId":"NCT00764790","phase":"PHASE3","title":"Immunogenicity and Safety of GSK Biologicals' Influenza Vaccine Versus a Licensed Comparator in Children","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2008-10-01","conditions":"Influenza","enrollment":3317},{"nctId":"NCT02545543","phase":"PHASE3","title":"A Study to Evaluate the Immunogenicity and Safety of Seqirus Quadrivalent Influenza Vaccine (QIV) in a Pediatric Population 5 Through 17 Years of Age","status":"COMPLETED","sponsor":"Seqirus","startDate":"2015-09","conditions":"Influenza, Human","enrollment":2278},{"nctId":"NCT00735475","phase":"PHASE4","title":"A Study to Determine the Immunogenicity and Safety Profile of CSL Limited's Influenza Virus Vaccine Compared to a US Licensed Comparator Influenza Virus Vaccine","status":"COMPLETED","sponsor":"Seqirus","startDate":"2008-10","conditions":"Influenza","enrollment":1268},{"nctId":"NCT02655874","phase":"PHASE4","title":"Tropical Influenza Control Strategies for the Elderly","status":"COMPLETED","sponsor":"Tan Tock Seng Hospital","startDate":"2016-05","conditions":"Influenza, Human","enrollment":200},{"nctId":"NCT03184766","phase":"PHASE1","title":"Ibuprofen and Pseudoephedrine Comparative Pharmacokinetic Study","status":"COMPLETED","sponsor":"Reckitt Benckiser Healthcare (UK) Limited","startDate":"2016-08-10","conditions":"Healthy","enrollment":55},{"nctId":"NCT00959049","phase":"PHASE3","title":"A Study to Determine the Immunogenicity and Safety Profile of CSL Limited's Influenza Virus Vaccine Compared to a US Licensed Comparator Influenza Virus Vaccine in a Pediatric Population","status":"COMPLETED","sponsor":"Seqirus","startDate":"2009-09","conditions":"Influenza","enrollment":1474},{"nctId":"NCT02307851","phase":"PHASE2","title":"Quadrivalent Influenza VLP Vaccine Dose Ranging Study in Young Adults","status":"COMPLETED","sponsor":"Novavax","startDate":"2014-11","conditions":"Influenza","enrollment":400},{"nctId":"NCT02710409","phase":"PHASE3","title":"A Phase III Clinical Trial of An Inactivated Quadrivalent Influenza Vaccine in Healthy Subjects Aged 3 Years and Older","status":"COMPLETED","sponsor":"Jiangsu Province Centers for Disease Control and Prevention","startDate":"2016-01","conditions":"Influenza","enrollment":3664},{"nctId":"NCT02126761","phase":"PHASE1","title":"Safety and Immunogenicity of Different Formulations of an Adjuvanted, Trivalent Subunit Influenza Vaccine in Elderly Subjects 65 Years of Age and Above","status":"COMPLETED","sponsor":"Seqirus","startDate":"2014-06","conditions":"Influenza","enrollment":196},{"nctId":"NCT01152814","phase":"PHASE2","title":"Study to Evaluate Safety and Immunogenicity of Sub-unit Adjuvanted Influenza Vaccine Administered to Elderly Subjects, Formulation 2010-2011","status":"COMPLETED","sponsor":"Novartis Vaccines","startDate":"2010-06","conditions":"Seasonal Influenza","enrollment":64},{"nctId":"NCT01068912","phase":"PHASE2","title":"Dose-Finding Study of Favipiravir in the Treatment of Uncomplicated Influenza","status":"COMPLETED","sponsor":"MDVI, LLC","startDate":"2010-02","conditions":"Influenza","enrollment":530},{"nctId":"NCT02139228","phase":"PHASE3","title":"Persistency Study After Hib-CRM (Cross-Reacting Material)197 or Hib-TT (Tetanus Toxoid) Vaccines in Chinese Children","status":"COMPLETED","sponsor":"Novartis Vaccines","startDate":"2014-11","conditions":"Meningitis, Epiglottitis, Pneumonia, Arthritis Caused by Haemophilus Influenzae Type b","enrollment":426},{"nctId":"NCT02212106","phase":"PHASE4","title":"A Study to Evaluate the Safety and Tolerability of Trivalent Influenza Virus Vaccine in Children Aged 5 Years to < 9 Years","status":"COMPLETED","sponsor":"Seqirus","startDate":"2014-09","conditions":"Influenza, Human","enrollment":402},{"nctId":"NCT00464672","phase":"PHASE3","title":"Safety, and Immunogenicity of Two Influenza Vaccines in Healthy Subjects 3 to 64 Years Old","status":"COMPLETED","sponsor":"Novartis","startDate":"2007-04","conditions":"Influenza","enrollment":1893},{"nctId":"NCT00231816","phase":"PHASE3","title":"A Study of an Investigational Zoster Vaccine in Subjects With a History of Varicella (Chickenpox) Given Concomitantly With Another Vaccine (V211-011)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2005-09","conditions":"Herpes Zoster","enrollment":763},{"nctId":"NCT02434276","phase":"PHASE2","title":"Study of the Immunogenicity and Safety of a Quadrivalent Influenza Vaccine (VAX2012Q) in Adults 18-64 Years","status":"UNKNOWN","sponsor":"VaxInnate Corporation","startDate":"2015-05","conditions":"Influenza","enrollment":450},{"nctId":"NCT01332578","phase":"PHASE4","title":"A Comparison of Solid and Soluble Forms of Cold and Influenza Remedies","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2011-05","conditions":"Influenza, Common Cold","enrollment":25},{"nctId":"NCT01346592","phase":"PHASE3","title":"Safety, Tolerability, and Immunogenicity of the Adjuvanted Trivalent Subunit Influenza Vaccine and the Non-Adjuvanted Trivalent Subunit Influenza Vaccine Compared to the Non-Adjuvanted Trivalent Split Influenza Vaccine in Children 6 to < 72 Months of Age","status":"COMPLETED","sponsor":"Novartis Vaccines","startDate":"2011-04","conditions":"Influenza Disease","enrollment":6104},{"nctId":"NCT00441012","phase":"PHASE3","title":"Study of Modified Process Hib/Hep B Vaccine in Infants (V121-019)(COMPLETED)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2006-12","conditions":"Haemophilus Influenzae Type B, Hepatitis B","enrollment":546},{"nctId":"NCT00851266","phase":"PHASE1","title":"A Study of a Bivalent Influenza Peptide Conjugate Vaccine in Healthy Adults","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2006-10","conditions":"Influenza","enrollment":187},{"nctId":"NCT01224795","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Intravenous Peramivir in Subjects With Uncomplicated Influenza.","status":"TERMINATED","sponsor":"BioCryst Pharmaceuticals","startDate":"2010-10","conditions":"Influenza","enrollment":1},{"nctId":"NCT02330003","phase":"PHASE1","title":"Phase 1 Study to Assess the Safety of Inactivated Split Influenza Vaccine and Control Vaccine in Korean Volunteer","status":"COMPLETED","sponsor":"Il-Yang Pharm. Co., Ltd.","startDate":"2013-05","conditions":"Healthy","enrollment":100},{"nctId":"NCT01419925","phase":"PHASE2","title":"A Study to Assess the Safety and Immunogenicity of M-001 Influenza Vaccine as a Primer to TIV in Elderly Volunteers","status":"COMPLETED","sponsor":"BiondVax Pharmaceuticals ltd.","startDate":"2011-08","conditions":"Influenza, Healthy","enrollment":120},{"nctId":"NCT00979251","phase":"PHASE2","title":"Oral Triple Combination Antiviral Drug Therapy for Treatment of Influenza A in Immunocompromised Subjects","status":"COMPLETED","sponsor":"Adamas Pharmaceuticals, Inc.","startDate":"2009-09","conditions":"Influenza","enrollment":2},{"nctId":"NCT01209780","phase":"PHASE3","title":"Safety and Immunogenicity of Trivalent Subunit Inactivated Flu Vaccine Administered to Healthy Children and Adolescents 3 to 17 Years of Age","status":"COMPLETED","sponsor":"Novartis Vaccines","startDate":"2010-09","conditions":"Seasonal Influenza","enrollment":3116},{"nctId":"NCT00848887","phase":"PHASE1","title":"A Dose Ranging Study Comparing Different Combinations of Adjuvanted and Non-adjuvanted Influenza Vaccines in Healthy Children 6 to <36 Months of Age","status":"COMPLETED","sponsor":"Novartis","startDate":"2008-10","conditions":"Influenza","enrollment":410},{"nctId":"NCT00513669","phase":"PHASE1","title":"Phase Ib Trial of Two Virosome Formulated Malaria Vaccine Components (PEV 301, PEV 302) in Tanzania","status":"COMPLETED","sponsor":"Swiss Tropical & Public Health Institute","startDate":"2008-01","conditions":"Falciparum Malaria","enrollment":50},{"nctId":"NCT00975572","phase":"PHASE2","title":"Novel Influenza A/H1N1 Split- Virion Vaccine in Healthy Population Aged 3 Years and Older","status":"COMPLETED","sponsor":"Jiangsu Province Centers for Disease Control and Prevention","startDate":"2009-07","conditions":"Virus Diseases, Respiratory Tract Diseases, Respiratory Tract Infections","enrollment":2200}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":4832,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Fluzone, Vaxigrip"],"phase":"phase_3","status":"active","brandName":"Comparator: Influenza Vaccine","genericName":"Comparator: Influenza Vaccine","companyName":"Merck Sharp & Dohme LLC","companyId":"merck","modality":"Biologic","firstApprovalDate":"","aiSummary":"Influenza vaccine stimulates the immune system to produce antibodies and cellular immunity against influenza virus strains, providing protection against infection. Used for Seasonal influenza prevention in adults and children.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}